Cytek Biosciences (CTKB) Net Cash Flow (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Net Cash Flow data on file, last reported at -$25.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1064.74% year-over-year to -$25.8 million; the trailing twelve-month figure through Mar 2026 stood at -$31.6 million (up 58.1% YoY), and the FY2025 full-year result was -$8.0 million, up 89.1% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$25.8 million, down from -$3.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $30.6 million in Q3 2023 and bottomed at -$166.0 million in Q1 2023.
• The 5-year median for Net Cash Flow is -$3.8 million (2025), against an average of -$17.7 million.
• The widest annual swing landed in 2023, when Net Cash Flow slumped 8656.12%; it then jumped 4076.28% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$41.0 million in 2022, then surged by 111.76% to $4.8 million in 2023, then slumped by 1449.0% to -$65.1 million in 2024, then surged by 94.1% to -$3.8 million in 2025, then plunged by 572.94% to -$25.8 million in 2026.
• The last three Net Cash Flow figures came in at -$25.8 million (Q1 2026), -$3.8 million (Q4 2025), and $17.0 million (Q3 2025), per Business Quant data.

Peer Comparison